publication date: Sep. 5, 2014

html Alchemist.html


NCI launched another in a series of targeted treatment trials referred to as the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial.

ALCHEMIST seeks to identify mutations in early-stage lung cancer patients, and uses this information to assign them to treatments targeted for those mutations.

“We believe that the findings from ALCHEMIST will not only help answer an important question about the addition of targeted therapies in earlier stage disease, but will also help us in understanding the prevalence and natural history of these genomic changes in earlier stage lung cancer,” Shakun Malik, head of Thoracic Cancer Therapeutics in the NCI Clinical Investigations Branch, said in a statement. “We also hope to gain a better understanding regarding the genetic changes in the tumor at the time of recurrence.

“The findings will help to define clinical, biologic and molecular behaviors of this type of lung cancer.”

ALCHEMIST is coordinated by the Alliance for Clinical Trials in Oncology and the ECOG-ACRIN Cancer Research Group.

All of the NCI-supported National Clinical Trials Network groups collaborated in the development of ALCHEMIST and are participating in the component trials.

Patients enrolled in ALCHEMIST have been diagnosed with lung adenocarcinoma or similar types of lung cancer as identified by examining the tissue; will undergo surgical removal of their tumors; and will need to complete standard therapy after surgery, consisting of chemotherapy with or without radiation therapy, as prescribed by their physician.

Continue reading 40-33 Alchemist

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.